{"name":"RedHill Biopharma Limited","slug":"redhill-biopharma-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"RHB-102","genericName":"RHB-102","slug":"rhb-102","indication":"Nausea and vomiting associated with chemotherapy","status":"phase_3"},{"name":"Opaganib","genericName":"Opaganib","slug":"opaganib","indication":"Other","status":"discontinued"},{"name":"BEKINDA","genericName":"BEKINDA","slug":"bekinda","indication":"Prevention of nausea and vomiting associated with chemotherapy and radiation therapy","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"RHB-105","genericName":"RHB-105","slug":"rhb-105","indication":"Treatment of COVID-19","status":"phase_3"},{"name":"Rifamycin SV MMX","genericName":"Rifamycin SV MMX","slug":"rifamycin-sv-mmx","indication":"Clostridioides difficile infection (CDI)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"RHB-104","genericName":"RHB-104","slug":"rhb-104","indication":"Crohn's disease (moderate to severe, MAP-positive or MAP-negative)","status":"phase_3"}]}],"pipeline":[{"name":"RHB-102","genericName":"RHB-102","slug":"rhb-102","phase":"phase_3","mechanism":"RHB-102 is a gastric motility agent.","indications":["Nausea and vomiting associated with chemotherapy"],"catalyst":""},{"name":"Opaganib","genericName":"Opaganib","slug":"opaganib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEKINDA","genericName":"BEKINDA","slug":"bekinda","phase":"phase_2","mechanism":"Bekinda is a delayed-release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.","indications":["Prevention of nausea and vomiting associated with chemotherapy and radiation therapy"],"catalyst":""},{"name":"RHB-104","genericName":"RHB-104","slug":"rhb-104","phase":"phase_3","mechanism":"RHB-104 is a combination of three antibiotics (clarithromycin, rifabutin, and clofazimine) designed to target Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease.","indications":["Crohn's disease (moderate to severe, MAP-positive or MAP-negative)"],"catalyst":""},{"name":"RHB-105","genericName":"RHB-105","slug":"rhb-105","phase":"phase_3","mechanism":"RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"Rifamycin SV MMX","genericName":"Rifamycin SV MMX","slug":"rifamycin-sv-mmx","phase":"phase_3","mechanism":"Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.","indications":["Clostridioides difficile infection (CDI)","Traveler's diarrhea"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBqQTFObTlSZFpvTDJSaWlIeXhuSnVWbEY3bER6NnNqMlZjaEQ2OUdLSDJEQ29lc1cyUjZSLS00aGlvdDJsZFV2TlFuR2ZHRUhxa1poV2NKTWpac1VETTNr?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill","headline":"RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE43cVlRUTBIcXV2QkNiZWJhWFkxXzRQYmJkWnJVUzVVOFNkQUYycTJFUlFwSmQwOVdoR3Zkb1JSWi1XR1ktelRWcGxjLTQwMUZzektja1lfV2R3Q200UXc2cjAzR1dGUFM3Vml5WmlSeGZha0s3a0l5em95cXAyOXM?oc=5","date":"2026-01-05","type":"pipeline","source":"StocksToTrade","summary":"Could RedHill Biopharma’s Surge Ultra-Charge Its Growth? - StocksToTrade","headline":"Could RedHill Biopharma’s Surge Ultra-Charge Its Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcy1Oa25uZGRxd2JJNlRDaTllbnlZdUYyTjBPWXpRV01ETmVLbzJaM2QybWhDeWhtdDcwaC0xZTlqSmx0ZFZwZ1Fhbk0yM0p3aHVRSTVaWHFZM2RZU0MzRFBVaHc2V2E4ck5HY1lLX0R3aGNIbjZSLXNFVDB4NmN0TUlNbndIZUdOTkJWQ1JCX3RvVWttWVNHZ292RGxRclRvTjFrb3ZodHMxOFBYX29KdU5sdWpHcXhKbHJpZzhWTkkybmZLclh1eUF1Z3lBV1c5OUlVbGdYdGZkT2FBa3Bmc3l3NA?oc=5","date":"2025-12-01","type":"pipeline","source":"PR Newswire","summary":"RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PR Newswire","headline":"RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPYUp6OHZyaWxhQjB2UGhPdlptZjU1aUJFUVJiYTRyN0lMOE1uSk1ZWnBKcWsyR2FGLUx2MkRTTVBPNjlEMVVxdzRMbUp5ME96YkE0OWpwQ080LTRBd0NuSG5hNTR4VTZ3d1labE0yYVZlMTM3QlBuc0k0Wl9YeWNsTUYzZXQwbjgzSE56SWczbGV4dlB0ZzVJelNfVEZXZw?oc=5","date":"2025-11-05","type":"earnings","source":"Mexico Business News","summary":"Cumberland Pharmaceuticals Reports 12% Revenue Growth in 2025 - Mexico Business News","headline":"Cumberland Pharmaceuticals Reports 12% Revenue Growth in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQT3MwbmVpZVJ6LWh1VmhtdVRuQmNkVkVkWlRROGlKbmhGNVRtT2dOMk9TdlFWVVktTVplYmtkdVE5UGEtN2ZJYWhmcktSdktyQzJaUDNKUWRpSkUxWEFkM0E5bzFqM3paWW1JYjNsLTFsM2RlWFJCTllHdTBTWlZNN1RLSml5ZXE3eUVxTXgxNFNabkNDeWE2dk0yWmFBLU1MNGIzRVhoVzE1TW1IS2tYODlfV2E0b2wtamt2YW1xT1VxQllHUHdGbkVOcGlFY3U5MW9Ja3JNMmdhUTBRVUdXbHl5Sk83VHFKbkZCSg?oc=5","date":"2025-10-20","type":"deal","source":"PR Newswire","summary":"RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire","headline":"RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQaUtnaGNuTlVqdDNneDljdGZJQmU2UVc5LXRKZjVLaGkyd3BHcXJCTFgtWW8tT0VjNmZrMVplckFnQ1JZTFY1YVlWOFV6c2JwOHFRd2s4Wk9ydDl3RkxKZmZtaXhpQW1qSjMtc3llZkhTai1mcTVCbWtIQXk4X3dnSzU5MmFQUE9vRGlSOHBxMVYyeVhFVG5HQXJEcF9PZDIxUXhzN1p3SFJjMzlsY0pOZHBKVWZ6LTNZU043TG93?oc=5","date":"2025-10-20","type":"regulatory","source":"Stock Titan","summary":"$8M 2024 Talicia Revenue — Cumberland to Commercialize FDA‑Approved H. pylori, $4M Investment - Stock Titan","headline":"$8M 2024 Talicia Revenue — Cumberland to Commercialize FDA‑Approved H. pylori, $4M Investment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNbFBHN2c0SDREWFg2YVBNZ3ZrUHc3aHVrUVpfVWRrMUk2VzF3YmhLQmRDM0JOWTR5MlAtcHMtNG5jSzFvRmJuRTJ5RGZMOHU3TjRNYTRscmwwQ0Y2elJkZmI4ZVJkU2VSVmVyTXJSendnYjJtOU15UlRhMGR5UENSNkVLdGtFdnJxcUtweThRNXY0YldWdEZ5NzJ6OGcwM1BWRTZ1MmFZWUYxeGJOV3hEcEswM09WTTBsb091b01PNlkydnFvOXR0YVVUY0xtZ3BLNzZtLVV1dTlMLW5XdHc?oc=5","date":"2025-10-06","type":"deal","source":"PR Newswire","summary":"RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PR Newswire","headline":"RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPY0ZaZ0g2YXlXY3dPMVJYWlBtdlQ2enNBYWtLaWZrTEc2WUF1YjFIbHRtNDJfN1pjSG5nU18tMlRmeTlMWW5zNFFuZnRGc2VsdXBvTGY3R0Jsc25mVnNRT3I0ZktIdDNidkctVEcwY1ZBc1BkYlFlYnJEa0FzMklocFlzWU5NNHByOGl0eGdZVDhuNUpSTlRHdC1iQTlpZmV2VlNaNTFsc0JQckxvU2MtYXBhQ0hEbm9pS3pCdkExU2Y3VWRQQ0ltOWM5TWc2YVBQMUJOWWE5ektXSmJNR2wyU3RKNzUzUQ?oc=5","date":"2025-04-17","type":"pipeline","source":"PR Newswire","summary":"RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire","headline":"RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTmZraXA3cUQ5NURrZHloSzNONVk2OE1FUFZwdy00LVlhLXlmdkZld05QN19VODQ5MTJlakxMd2g4OFZQckZQVktKN0JCNDV3V0NrWmpEYWNWc0RFcGYtbFlYZlNWNzdUcnEwc0lTOUF3Wml6SlY4cG9JVnkwRER2TTBIcDF6QnFT?oc=5","date":"2025-02-25","type":"deal","source":"Contract Pharma","summary":"RedHill Licenses RHB-102 to Hyloris - Contract Pharma","headline":"RedHill Licenses RHB-102 to Hyloris","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxNQ2ZFTnJ5OW1iRGRUcjlSVnpqdTZIeWVPTTA2cDJvX1VjM0xmOXgzV1NuLTV5bUY5RERRM25IX3hadk5NaHpzckttT21pYTI5RFZSVkxmSVFtSG1Pb3JWWUdrLXpQM24wbGtSTko0ZHpIM1BnYlpPXzE2MGx1RWxnU1dIYl9oTHdmTUNra3NEYjdfazY1al9BUk1pY2lxZHdKZTB4bDlJNS1BMWF2ODdkQ2U4M3NMQmp3bjB3MzdfVzFUbS1yZ3hPSkZqcWc2TFI3U2Z6engtUTRIMDhUbUhvQi1rTXhmS1FqVWlKTVZiNlF5U0h5dUJtcXhMY2txd1hfWFV6WGc4WUFOSDhQaGtIQUlhYWpUYWx3SWpyY3cyVENHSlEzcnZ6Y1dRVGF3TV9mcGk4RUV6UVY5NmtGNDVpR1RMeVFjNzRkcWQteTNINHQ4WFZ6?oc=5","date":"2025-01-28","type":"regulatory","source":"Barchart.com","summary":"Irritable Bowel Syndrome Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Bio ","headline":"Irritable Bowel Syndrome Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveIns","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPZVFKS0llbFdXT2QyWXN6Yk93WEp3WDV5V3JUc2ZCUTM0ZTl1dksyRGZnOURIbzB1LXU2cjk3V2lyY2xpdGQzT1dGU3Q1Ukl3VDdZWkVlMWlMV1JqUmNsNWRXbUhXWHhNdXNPS2F1bnlIS2p0VC1fV1RHZ01fTWQwWnVrWjh4VTVsYk91VFVCZ201cjhwLThPQjFQemE2NUxXU0NWRmY3MWRPMFJRR0VTNk5iWlBQY3dhQWJraVkzS2lOQ2w5VXozUHo5cS1DdDVBNDBLeVY1Zmh2U2pfbFpCQmZWRXNvMGJFUzJwaHY5b0s4a2VFUjdLY2ZwRkdTNDhm?oc=5","date":"2024-10-17","type":"pipeline","source":"GlobeNewswire","summary":"Ebola Virus Drug Development Pipeline Expands with Contributions from 18+ Key Companies | DelveInsight - GlobeNewswire","headline":"Ebola Virus Drug Development Pipeline Expands with Contributions from 18+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPZmRlLXIxSE4yV2txT0JoWU5nY2F6Sm5rUjdWR2VWbnJaWHYyOTdBMWg2RkFtbjV1UXk5UXctaXBMa2JILUY3RXN5QzNaWlllaGgyV3Qzal9tcFA1VTFkOW0tQ193VEJKTmZzZ0ExMjdMcWd4SVJFVnJSZnlSXzZKU1RQdFJMZTVLTUwyMDhZTWxpY1lMRV9UY1h4R3c0SnV0X05ncTl5UWNuaThCdWJR?oc=5","date":"2024-08-21","type":"pipeline","source":"Contract Pharma","summary":"RedHill Biopharma Launches Talicia for H. pylori Infection in UAE - Contract Pharma","headline":"RedHill Biopharma Launches Talicia for H. pylori Infection in UAE","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":4,"discontinued":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}